Re: [177Lu]Lu-PSMA-617 in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-naive/sensitive Prostate Cancer (PSMAddition): A Phase 3 Randomised, Controlled Trial.

Pluvicto (lutetium Lu 177 vipivotide tetraxetan) - Novartis

Re: [177Lu]Lu-PSMA-617 in Patients with PSMA-positive Metastatic Androgen Pathway Modulator-naive/sensitive Prostate Cancer (PSMAddition): A Phase 3 Randomised, Controlled Trial. (PubMed, Eur Urol) - Oct 1, 2026 - No abstract available
Journal • P3 data • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor

http://www.ncbi.nlm.nih.gov/pubmed/42816307

Alberto Briganti; Alessandro Viti; Francesco Montorsi; Giorgio Gandaglia; Vito Cucchiara

Oct 1, 2026